India to draw blueprint to curb spurious and not-of-standard medicines soon
International consultation on developing blueprint to combat spurious drugs with use of technology
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Ginkgo biloba extract does not prevent Alzheimer’s dementia
The randomised, double-blind trial took place over five years, involving 2,854 people in France who were 70 years old or over
Venus Remedies bags first patent from Canada for Vancoplus
Venus Remedies plans to launch the product in Canada in next two years
Aurobindo Pharma receives US FDA approval for amlodipine besylate and benazepril hydrochloride…
Products have been approved out of Aurobindo Pharma's Unit VII (SEZ) formulations facility in Hyderabad Aurobindo Pharma has…
US FDA approves new orphan drug for chronic myelogenous leukaemia
The safety and effectiveness of Bosulif was evaluated in a single clinical trial that enrolled 546 adult patients
New data for Novartis Lucentis confirms efficacy, safety profile of individualised treatment
Novartis will submit for regulatory approval in this indication in the EU in the third quarter of this year and in Japan by 2012…
AYUSH proposes to set up Central Drug Controller Office
Gets approval of Rs 80 lakhs from Department of Expenditure
Phenomenex launches Kinetex Core-Shell Technology
Kinetex delivers improved results on any LC instrument
US FDA to continue review of Crofelemer new drug application
FDA action on Crofelemer NDA Anticipated by end of 1Q-CY2013
Cole-Parmer releases 6th annual catalogue for India market
The 288-page catalogue has numerous unique and new products